The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis
Open accessAbstract
PA-824 is a promising new compound for the treatment of tuberculosis that is currently undergoing human trials. Like its progenitors metronidazole and CGI-17341, PA-824 is a prodrug of the nitroimidazole class, requiring bioreductive activation of an aromatic nitro group to exert an antitubercular effect. We have confirmed that resistance to PA-824 (a nitroimidazo-oxazine) and CGI-17341 (a nitroimidazo-oxazole) is most commonly mediated by loss of a specific glucose-6-phosphate dehydrogenase (FGD1) or its deazaflavin cofactor F 420 , which together provide electrons for the reductive activation of this class of molecules. Although FGD1 and F 420 are necessary for sensitivity to these compounds, they are not sufficient and require additional accessory proteins that directly interact with the nitroimidazole. To understand more proximal events in the reductive activation of PA-824, we examined mutants that were wild-type for both FGD1 and F 420 and found that, although these mutants had acquired high-level resistance to PA-824 (and another nitroimidazo-oxazine), they retained sensitivity to CGI-17341 (and a related nitroimidazo-oxazole). Microarray-based comparative genome sequencing of these mutants identified lesions in Rv3547, a conserved hypothetical protein with no known function. Complementation with intact Rv3547 fully restored sensitivity to nitroimidazo-oxazines and restored the ability of Mtb to metabolize PA-824. These results suggest that the sensitivity of Mtb to PA-824 and related compounds is mediated by a protein that is highly specific for subtle structural variations in these bicyclic nitroimidazoles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Self-citationSnapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Self-citationCamacho, L. R., Ensergueix, D., Perez, E., Gicquel, B., & Guilhot, C. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01593.x · Cited by 621
Comprehensive identification of conditionally essential genes in mycobacteria
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231275498 · Cited by 616
Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action
Edwards, D. I. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.1.9 · Cited by 606
Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis
Pelicic, V., Jackson, M., Reyrat, J.-M., Jacobs, W. R., Gicquel, B., & Guilhot, C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10955 · Cited by 423
Dormancy ofMycobacterium tuberculosis and latency of disease
Wayne, L. G. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02111491 · Cited by 387
Contribution of the Mycobacterium tuberculosis MmpL Protein Family to Virulence and Drug Resistance
Domenech, P., Reed, M. B., & Barry, C. E. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3492-3501.2005 · Cited by 361
Self-citationMetronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis
Wayne, L. G., & Sramek, H. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2054 · Cited by 295
Why Metronidazole Is Active against both Bacteria and Parasites
Samuelson, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1533 · Cited by 231
The genetics and biochemistry of isoniazid resistance in
Slayden, R. A., & Barry, C. E. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)00359-2 · Cited by 205
Self-citationSisson, G., Goodwin, A., Raudonikiene, A., Hughes, N. J., Mukhopadhyay, A. K., Berg, D. E., & Hoffman, P. S. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2116-2123.2002 · Cited by 167
Prospects for new antitubercular drugs
Duncan, K., & Barry, C. E. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.08.011 · Cited by 132
Self-citationPlatt, R., Drescher, C., Park, S., & Phillips, G. J. (2000) · Plasmid · doi:10.1006/plas.1999.1433 · Cited by 129
Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Barry, C. E., Boshoff, H. I., & Dowd, C. S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383214 · Cited by 128
Self-citationWong, C. W., Albert, T. J., Vega, V. B., Norton, J. E., Cutler, D. J., Richmond, T., Stanton, L. W., Liu, E. T., & Miller, L. D. (2004) · Genome Research · doi:10.1101/gr.2141004 · Cited by 127
Self-citationLight-directed 5'->3' synthesis of complex oligonucleotide microarrays
Albert, T. J., Norton, J., Ott, M., Richmond, T., Nuwaysir, K., Nuwaysir, E. F., Stengele, K.-P., & Green, R. D. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng035 · Cited by 113
Self-citationChoi, K.-P., Kendrick, N., & Daniels, L. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.9.2420-2428.2002 · Cited by 108
Self-citationChoi, K.-P., Bair, T., Bae, Y.-M., & Daniels, L. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.24.7058-7066.2001 · Cited by 96
Self-citationPurwantini, E., Gillis, T. P., & Daniels, L. (1997) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1997.tb10182.x · Cited by 80
Self-citationStructures of coenzyme F 420 in Mycobacterium species
Bair, T., Isabelle, D., & Daniels, L. (2001) · Archives of Microbiology · doi:10.1007/s002030100290 · Cited by 51
Self-citationReduction of nitroimidazole derivatives by hydrogenosomal extracts of Trichomonas vaginalis
Yarlett, N., Gorrell, T. E., Marczak, R., et al. (1985) · Molecular and Biochemical Parasitology · doi:10.1016/0166-6851(85)90103-3 · Cited by 51
Reactivity of Reduced [2Fe-2S] Ferredoxins Parallels Host Susceptibility to Nitroimidazoles
Vidakovic, M., Crossnoe, C. R., Neidre, C., Kim, K., Krause, K. L., & Germanas, J. P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.302-308.2003 · Cited by 41
Crossnoe, C. R., Germanas, J. P., Maguerès, P. L., Mustata, G. I., & Krause, K. L. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00051-7 · Cited by 29
Cited by
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R. J., & Young, D. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,422
Self-citationAdvances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740
Gagneux, S., & Small, P. M. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70108-1 · Cited by 712
Metadata
- Authors
- Manjunatha, U. H., Boshoff, H., Dowd, C. S., Zhang, L., Albert, T. J., Norton, J. E., Daniels, L., Dick, T., Pang, S. S., & Barry, C. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-12-30
- Volume
- 103
- Issue
- 2
- Pages
- 431-436
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2010320265
- Cited by
- 331
- References
- 25
- FWCI
- 11.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.